白细胞介素-6 在多发性硬化症中的治疗潜力。

Therapeutic potential of LIF in multiple sclerosis.

机构信息

Hasselt University, Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium.

出版信息

Trends Mol Med. 2010 Nov;16(11):493-500. doi: 10.1016/j.molmed.2010.08.007. Epub 2010 Oct 1.

DOI:10.1016/j.molmed.2010.08.007

PMID:20870461

Abstract

Therapies for multiple sclerosis (MS) reduce the relapse rate but are unable to stop neurological decline. Here, we evaluate the potential of leukemia inhibitory factor (LIF) as a novel therapeutic in diseases with a neurodegenerative and inflammatory component, such as MS. LIF, which can be a proinflammatory cytokine, can also modulate the immune response in a beneficial way. Recent evidence demonstrates a crucial role of LIF in neuroprotection and axonal regeneration as well as the prevention of demyelination. Finally, LIF is an important survival factor for stem cells and neuronal precursors. Therefore, we propose that LIF is a potential therapeutic candidate for MS.

摘要

多发性硬化症（MS）的治疗方法可以降低复发率，但无法阻止神经功能下降。在这里，我们评估白血病抑制因子（LIF）作为一种新型治疗方法的潜力，这种方法适用于具有神经退行性和炎症成分的疾病，如 MS。LIF 可以作为一种促炎细胞因子，也可以以有益的方式调节免疫反应。最近的证据表明，LIF 在神经保护、轴突再生以及防止脱髓鞘方面起着至关重要的作用。最后，LIF 是干细胞和神经前体细胞的重要生存因子。因此，我们提出 LIF 是 MS 的潜在治疗候选物。